Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067442 | 0.88 | TUBB4A (0.54) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL11248414 | 0.85 | HSD17B10 (0.49) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL20489173 | 0.85 | MTNR1A (0.52) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL20488495 | 0.85 | HTR2A (0.47) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL25308876 | 0.84 | ADRA1A (0.68) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL1492044 | 0.83 | APLNR (0.63) | HTR2AIDO1ADRA1ATAAR1CA12 | |
| SCHEMBL2060421 | 0.83 | HTR2A (0.47) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL5252421 | 0.83 | IDO1 (0.66) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL3202940 | 0.82 | TACR1 (0.46) | HTR2AIDO1ADRA1ATAAR1HTR2C | |
| SCHEMBL7414770 | 0.82 | HTR2A (0.49) | HTR2AIDO1ADRA1ATAAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013739-B1 | NEW TELESCOPING SYNTHESES OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE | WELLA GERMANY GMBH (DE) | 2024-10-02 | — | — | EP | claimed |
| CN-114787122-A | Novel polycondensation synthesis of 2-methoxymethyl-p-phenylenediamine | 威娜德国有限责任公司 | 2022-07-22 | — | — | CN | claimed |
| EP-4013739-A1 | NEW TELESCOPING SYNTHESES OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE | Wella Germany GmbH (DE) | 2022-06-22 | — | — | EP | claimed |
| CN-112538025-A | Preparation method of fluorine-containing compound for hydrophobic surface treatment agent | 湖北福力德鞋业有限责任公司 | 2021-03-23 | — | — | CN | claimed |
| CN-112321413-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| JP-5070400-A | — | — | None | — | — | JP | disclosed |
| US-20250243216-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-114787122-B | Novel fold condensation of 2-methoxymethyl-p-phenylenediamine | 威娜德国有限责任公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025016469-A1 | ALKOXY THIOPHENE ACYL ARYLAMINE COMPOUNDS AND USE THEREOF | 复旦大学 | 2025-01-23 | — | — | WO | disclosed |
| US-12162892-B2 | CD16a binding agents and uses thereof | KLEO PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4013739-B1 | NEW TELESCOPING SYNTHESES OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE | WELLA GERMANY GMBH (DE) | 2024-10-02 | — | — | EP | disclosed |
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | CENTRE NAT RECH SCIENT (FR) | 2024-05-30 | — | — | US | disclosed |
| EP-0009386-B1 | 2,10-DISUBSTITUTED DIBENZO(B,D)PYRANS AND BENZO(C)QUINOLINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1982-11-17 | — | — | EP | disclosed |
| US-4347375-A | Process for preparing amino acids and esters | MERCK & CO., INC. (US) | 1982-08-31 | — | — | US | disclosed |
| EP-0007615-B1 | PROCESS FOR PREPARING AMINO ACIDS AND ESTERS | MERCK & CO. INC. (US) | 1982-06-16 | — | — | EP | disclosed |
| US-4275220-A | N-(BENZYLIDENE OR ALKYLIDENE)-2-AMINOCROTONATE CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4206225-A | ANALGESICS | PFIZER INC. (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0009386-A1 | 2,10-Disubstituted dibenzo(b,d)pyrans and benzo(c)quinolines and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-04-02 | — | — | EP | disclosed |
| EP-0008657-A1 | Alpha-vinyl-alpha-aminoacids and their esters and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1980-03-19 | — | — | EP | disclosed |
| EP-0007615-A2 | Process for preparing amino acids and esters | MERCK & CO. INC. (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243216-A1 | CD16A BINDING AGENTS AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | HTR2A 763/4885IDO1 1888/4885ADRA1A 915/4885 |
| US-12162892-B2 | CD16a binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | HTR2A 763/4885IDO1 1888/4885ADRA1A 915/4885 |
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | H1-2, H1-3, H1-0 | HTR2A 1041/4885IDO1 526/4885ADRA1A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.